BCAX Bicara Therapeutics Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Bicara Therapeutics Inc. (BCAX) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Net proceeds ~$161.8M from offering of 7,175,000 firm shares + 2,200,000 pre-funded warrants at $16.00/share public price
• Underwriters exercised full 30-day overallotment option (1,406,250 additional shares) on Feb 25, 2026 — signals strong institutional demand

+3 more insights

Item 2.02 · Results of Operations and Financial Condition

• Cash, cash equivalents, and investments ~$414.8M as of Dec 31, 2025 — preliminary, unaudited figure
• Disclosed in connection with an active equity offering (prospectus supplement), signaling dilution risk

+1 more insights

Get deeper insights on Bicara Therapeutics Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.